Cetera Investment Advisers Purchases 374 Shares of Align Technology, Inc. $ALGN

Cetera Investment Advisers boosted its position in shares of Align Technology, Inc. (NASDAQ:ALGN) by 4.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,451 shares of the medical equipment provider’s stock after buying an additional 374 shares during the period. Cetera Investment Advisers’ holdings in Align Technology were worth $1,789,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. True Wealth Design LLC boosted its position in shares of Align Technology by 7,650.0% during the 2nd quarter. True Wealth Design LLC now owns 155 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 153 shares in the last quarter. Cromwell Holdings LLC lifted its stake in Align Technology by 2,900.0% during the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 174 shares during the last quarter. SVB Wealth LLC bought a new stake in Align Technology during the first quarter worth $36,000. Farther Finance Advisors LLC boosted its holdings in shares of Align Technology by 42.2% in the 2nd quarter. Farther Finance Advisors LLC now owns 310 shares of the medical equipment provider’s stock valued at $59,000 after purchasing an additional 92 shares in the last quarter. Finally, Assetmark Inc. increased its stake in shares of Align Technology by 327.6% in the 2nd quarter. Assetmark Inc. now owns 449 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 344 shares during the last quarter. 88.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ALGN shares. Needham & Company LLC restated a “hold” rating on shares of Align Technology in a research report on Thursday, October 30th. Leerink Partners increased their target price on shares of Align Technology from $172.00 to $189.00 in a report on Thursday, October 30th. Wells Fargo & Company reduced their price target on shares of Align Technology from $199.00 to $181.00 and set an “overweight” rating on the stock in a research note on Thursday, October 30th. Weiss Ratings lowered shares of Align Technology from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, October 8th. Finally, Piper Sandler reissued an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Align Technology in a research note on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $175.45.

Align Technology Price Performance

NASDAQ:ALGN opened at $147.14 on Monday. Align Technology, Inc. has a one year low of $122.00 and a one year high of $246.19. The company has a market cap of $10.56 billion, a PE ratio of 28.51, a P/E/G ratio of 1.49 and a beta of 1.84. The firm’s 50 day simple moving average is $134.45 and its 200 day simple moving average is $156.20.

Align Technology (NASDAQ:ALGN) last released its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $2.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.23. The firm had revenue of $995.69 million during the quarter, compared to the consensus estimate of $980.75 million. Align Technology had a net margin of 9.50% and a return on equity of 14.06%. The company’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.35 earnings per share. Align Technology has set its Q4 2025 guidance at EPS. Equities research analysts expect that Align Technology, Inc. will post 7.98 EPS for the current year.

Align Technology announced that its board has approved a share repurchase plan on Tuesday, August 5th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its stock is undervalued.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.